NCT02007096 is a Phase 2 clinical trial of Transabdominal Plane Block in Ventral Hernia, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT02007096?

NCT02007096 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT02007096?

Interventions in NCT02007096: Transabdominal Plane Block, Non Transabdominal Plane Block.

What condition does NCT02007096 study?

NCT02007096 studies Ventral Hernia, Umbilical Hernia, Incisional Hernia, Postoperative Complications, Pain, Postoperative.

Is NCT02007096 still recruiting?

NCT02007096 is currently completed. Last updated 17 January 2018.

Are results published for NCT02007096?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-01-17 · How we verify

NCT02007096

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transabdominal Plane (TAP) Blocks in Ventral Hernia Repair

Completed Phase 2 Results posted Last updated 17 January 2018

What this trial tests

Phase 2 trial testing Transabdominal Plane Block in Ventral Hernia in 127 participants. Completed in 1 October 2014.

Timeline

1 August 2012

Primary endpoint
1 October 2014

1 October 2014

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	127
Start date	1 August 2012
Primary completion	1 October 2014
Estimated completion	1 October 2014
Sites	1 location across United States

Drugs / interventions tested

Transabdominal Plane Block — full drug profile →
Non Transabdominal Plane Block — full drug profile →

Conditions studied

Ventral Hernia — all drugs for Ventral Hernia →
Umbilical Hernia — all drugs for Umbilical Hernia →
Incisional Hernia — all drugs for Incisional Hernia →
Postoperative Complications — all drugs for Postoperative Complications →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Ventral Hernia or Umbilical Hernia. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Post-operative Opioid Use
Time frame: up to 24 hours
Amount of opioids used by patients at certain time points.

Sponsor's own description

The purpose of this study is to determine if a Transabdominal Plane Block will decrease patient pain and pain medication use after a laparoscopic ventral (ventral, umbilical, incisional) hernia repair with mesh.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Review of Abdominal Meshes for Hernia Repair-Current Status and Emerging Solutions.
Najm A, Niculescu AG, Gaspar BS, Grumezescu AM, et al · · 2023 · cited 19× · PMID 38005054 · DOI 10.3390/ma16227124

Verify or expand the search:

Other recruiting trials for Ventral Hernia

Currently open trials in the same condition.

NCT06710795 — AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair · NA · active not recruiting
NCT06367309 — ExtrAperitoneaL Plasty vs Intraperitoneal oNlay mEsh in Ventral Hernia Repair · NA · recruiting
NCT06445504 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Hernia Surgery (Enable Hernia Repair) · NA · active not recruiting
NCT06611462 — STRONG for Surgery & Strong for Life - Intensive Prehabilitation for Risk Reduction in Ventral Hernia Repair · NA · recruiting
NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02007096 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 17 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02007096.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing